Fig. 1

Plasma chemokines reflect and predict crizotinib response in EML4-ALK positive non-small cell lung cancer patients. A Forest plots of multivariant COX analysis results for progression-free survival (PFS) and overall survival (OS); B Kaplan–Meier curves of PFS and OS for CCL20 concentration; C Heatmap of 7 significant chemokines between patients with PFS shorter than 6 months (NR, n = 32) and longer than 12 months (R, n = 15); D Box plots of 7 significant chemokines expression comparing responders (R, n = 15) and non-responders (NR, n = 32); E Plasma CCL20 and CCL15 levels in baseline samples and samples after disease progression (PD)